Merus (NASDAQ:MRUS) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday.

Other equities research analysts also recently issued reports about the company. ValuEngine downgraded Merus from a “buy” rating to a “hold” rating in a research report on Monday, September 24th. Wedbush reiterated an “outperform” rating and issued a $34.00 target price (up from $26.00) on shares of Merus in a research report on Friday, July 27th. Finally, Zacks Investment Research upgraded Merus from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Thursday, September 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $28.50.

NASDAQ:MRUS opened at $15.71 on Friday. The stock has a market capitalization of $446.61 million, a P/E ratio of -3.66 and a beta of -0.19. Merus has a 12 month low of $14.05 and a 12 month high of $26.74.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, July 26th. The biotechnology company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.33. The company had revenue of $11.84 million for the quarter, compared to the consensus estimate of $3.47 million. Merus had a negative return on equity of 67.34% and a negative net margin of 178.79%. As a group, analysts anticipate that Merus will post -2.6 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California Public Employees Retirement System bought a new stake in Merus during the second quarter worth approximately $228,000. Renaissance Technologies LLC increased its stake in Merus by 26.8% during the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock worth $1,097,000 after acquiring an additional 10,200 shares during the last quarter. Stanley Laman Group Ltd. increased its stake in Merus by 23.7% during the second quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock worth $1,306,000 after acquiring an additional 10,982 shares during the last quarter. DRW Securities LLC bought a new stake in Merus during the second quarter worth approximately $286,000. Finally, Millennium Management LLC bought a new stake in Merus during the first quarter worth approximately $267,000. 54.43% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Recommended Story: NASDAQ Stock Market Explained

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.